India's Cipla set for best week since July 2025

Cipla

24/04/2026 09:29

** Shares of India's Cipla CIPL.NS on track for 4.99% weekly gain, eyes best week since July 2025

** Stock down 0.42% at 1,300.5 rupees on the day vs Nifty 50 .NSEI drop of 1.42%

** Drugmaker received U.S. FDA approval for its Abbreviated New Drug Application for the generic equivalent of inhaler Ventolin HFA

** Motilal Oswal("neutral"; TP:1,306 rupees)says g-Ventolin to aid growth and strengthen respiratory portfolio; sees 6–8% earnings CAGR over FY26–28

** Citi ("buy", TP: 1,530 rupees) says approval is key to boosting confidence in pipeline; expects product to contribute$50-70 million in revenue

** CIPL rated "hold" on avg by 37 analysts; median PT 1,438 rupees

** YTD stock down 13.59% vs Nifty 50 down 8.86%

(Reporting by Devika Nair in Bengaluru)

((Devika.MadhusudhananNair@thomsonreuters.com;))